Medicaid

First Opinion By Matt Salo

Much Adu(helm) about nothing: New Alzheimer’s drug threatens state Medicaid budgets

First Opinion By Aytan Y. Bellin

My aunt’s ‘Kafkaesque journey’ to get the home care she needs

Pharmalot By Ed Silverman

Biogen’s new Alzheimer’s drug could cost Medicaid up to $2.2 billion a year

Pharmalot By Ed Silverman

Centene to pay $143 million to two states to settle allegations of overcharging Medicaid

Politics By Rachel Cohrs

Biden’s Medicaid pressure tactics could put his team at odds with hospitals

Pharmalot By Ed Silverman

Tennessee to become the first state to run a closed Medicaid drug formulary

First Opinion By Andrey Ostrovsky

Advice for the next CMS administrator’s first 100 days

First Opinion By Michael Hochman and Michelle Levander

Create a scorecard to help make safety-net providers accountable to patients and the public

First Opinion By Eric Letsinger and Alison Rein

Invest in community-based organizations to put health dollars where they are really needed

Pharmalot By Ed Silverman

Mallinckrodt loses a court case and is on the hook for $650 million in overdue Medicaid rebates

First Opinion By Eric Schneider

Super Tuesday results suggest that Americans ‘aren’t looking for big structural changes’ in health care

First Opinion By Wendy E. Parmet

Trump’s immigration policies will make the coronavirus pandemic worse

Pharmalot By Ed Silverman

Justice Department sues Mallinckrodt over ‘hundreds of millions of dollars’ in Medicaid rebates

Pharmalot By Ed Silverman

PBMs favor their own pharmacies in the Florida Medicaid program

Pharmalot By Ed Silverman

U.S. officials will let Novartis pay expenses for some Kymriah patients who must travel for treatment

First Opinion By Ira Byock and Eric Walsh

Hopewell House hospice has closed. You should care about that

Politics By Priyanka Dayal McCluskey — Boston Globe and Matt Stout — Boston Globe

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

Pharmalot By Ed Silverman

Pharmalittle: Five companies offer $50 billion deal to settle opioid suits; FDA approves record number of generics

Pharmalot By Ed Silverman

Most state Medicaid programs continue to restrict access to hepatitis C medicines

Pharmalot By Ed Silverman

A murky approach to tracking 340B drugs and Medicaid may yield double discounts in some states

Pharmalot By Ed Silverman

Avanir to pay $116 million to settle bribery charges, while two docs and former sales reps are indicted

Pharmalot By Ed Silverman

Mylan pays $30 million to settle charges of misleading investors over probe into EpiPen Medicaid rebates

Pharmalot By Ed Silverman

Few Americans took obesity drugs thanks to doctor doubts and spotty insurance

First Opinion By Chuck Grassley

Grassley: For Medicaid, greater transparency will open the door to better value and outcomes

Pharmalot By Ed Silverman

Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending